HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02696 HENLIUS

Market Closed 08-14 16:08:36

67.300

-0.750

-1.10%

High69.000	Low66.850	Vol279.01K
Open67.550	D1 Closing68.050	Amplitude3.16%
Mkt Cap36.68B	Tradable Cap23.42B	Total Shares545.00M
T/O18.81M	T/O Rate0.08%	Tradable Shares348.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"HENLIUS","latestPrice":67.3,"timestamp":1786694916006,"preClose":68.05,"halted":0,"volume":279006,"delay":0,"changeRate":-0.011021307861866276,"floatShares":348000000,"shares":545000000,"eps":1.7563976302114805,"marketStatus":"Market Closed","change":-0.75,"latestTime":"08-14 16:08:36","open":67.55,"high":69,"low":66.85,"amount":18809245,"amplitude":0.031594,"askPrice":67.3,"askSize":53600,"bidPrice":67.1,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":1.7568420763526507,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":68.05,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.5281005935877418,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2658553605","title":"Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658553605","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658553605?lang=en_us&edition=fundamental","pubTime":"2026-08-10 07:27","pubTimestamp":1786318021,"startTime":"0","endTime":"0","summary":"HLX43 and HLX3902 milestones put Shanghai Henlius Biotech’s pipeline in focus\nShanghai Henlius Biotech (SEHK:2696) has reported fresh progress in its oncology pipeline. Regulators in China cleared a new HLX43 clinical trial in advanced solid tumours, and the first patient received HLX3902 in an early prostate cancer study.\nSee our latest analysis for Shanghai Henlius Biotech.\nShanghai Henlius Biotech’s recent HLX43 and HLX3902 updates have arrived alongside a sharp shift in sentiment, with...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-advances-oncology-pipeline","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-advances-oncology-pipeline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","VGFPF","RGLO","FEBU","PMDE","BK4581","DCF","BK4585","VOTE","DECU","JOYT","BK4588","02696","HK0000165453.HKD","XBI","HK0000320223.HKD","HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD","GXDW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142513653","title":"Hong Kong Stock Movers: HENLIUS Surges Over 8% as 8 Research Findings Set for WCLC, Han Si Zhuang Enters NHS Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=1142513653","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142513653?lang=en_us&edition=fundamental","pubTime":"2026-08-07 15:12","pubTimestamp":1786086736,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) shares continued their upward momentum, rising over 8% in today's trading, bringing the weekly gain to more than 20%. As of the latest update, the stock was trading at 67.2 Hong Kong...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VXUS","HK0000306685.HKD","02696","HK0000306701.USD","KCAI","BK4588","HK0000320223.HKD","HK0000165453.HKD","NHS","HK0000320264.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153475871","title":"HENLIUS Schedules 21 August 2026 Board Meeting to Review 2026 Interim Results and Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=1153475871","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153475871?lang=en_us&edition=fundamental","pubTime":"2026-08-03 17:06","pubTimestamp":1785747964,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (HENLIUS) has set 21 August 2026 as the date for its upcoming Board meeting. Directors will review and approve the consolidated interim results for the six months ended...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188561348","title":"Hong Kong Stocks in Focus: HENLIUS Surges Over 7% Afternoon as HLX43 Thymic Squamous Data and H-Antibody Lung Cancer Findings Set for Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=1188561348","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188561348?lang=en_us&edition=fundamental","pubTime":"2026-08-03 15:00","pubTimestamp":1785740444,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) climbed more than 7% in afternoon trading, rising 7.64% to HK$59.9 with a turnover of HK$31.025 million.On the news front, the 2026 World Conference on Lung Cancer (WCLC) is scheduled...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696","HK0000306701.USD","BK4588","HK0000165453.HKD","BK4585","VXUS","HK0000320223.HKD","KCAI","HK0000306685.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655363306","title":"Henlius Biotech Gets China Nod for Tumor Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2655363306","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655363306?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:18","pubTimestamp":1785496700,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (HKG:2696) obtained approval for its investigational new drug application for a clinical trial of HLX43 for injection from China's National Medical Products Administration.The","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000306685.HKD","BK4581","HK0000320264.USD","HK0000306701.USD","BK4585","02696","BK4588","HK0000320223.HKD","HK0000165453.HKD","BK1161","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176439300","title":"HENLIUS secures NMPA IND approval for PD-L1 ADC HLX43 combined with bevacizumab ± chemotherapy in advanced solid tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=1176439300","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176439300?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:48","pubTimestamp":1785487694,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (HENLIUS) announced that the National Medical Products Administration has cleared the investigational new drug (IND) application to initiate mainland China trials of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124877391","title":"HENLIUS Receives NMPA Approval for Clinical Trial of HLX43 Combination Therapy in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1124877391","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124877391?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:42","pubTimestamp":1785487323,"startTime":"0","endTime":"0","summary":"HENLIUS (02696) has announced that the National Medical Products Administration (NMPA) has approved its clinical trial application for HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), used in...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BMED","LU1169589451.USD","02696","BK4023","HK0000306701.USD","PD","PSYK","HK0000320223.HKD","IBBJ","HK0000320264.USD","HK0000306685.HKD","LU1169590202.USD","BK1161","MDTX","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655935698","title":"Shanghai Henlius Says China NMPA Clears HLX43-bevacizumab Trial in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2655935698","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655935698?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:31","pubTimestamp":1785486706,"startTime":"0","endTime":"0","summary":"Shanghai Henlius says China NMPA clears HLX43-bevacizumab trial in advanced solid tumorsChina’s NMPA cleared an IND to start mainland China trials of Henlius’s PD-L1 antibody-drug conjugate HLX43 with","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL6FCbBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","02696","HK0000306701.USD","HK0000306685.HKD","HK0000320264.USD","BK1161","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356624","title":"Shanghai Henlius Biotech - Nmpa Approves Hlx43 Clinical Trial Application in Combination with Bevacizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655356624?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:31","pubTimestamp":1785486678,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X0T5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000306701.USD","HK0000320223.HKD","HK0000165453.HKD","02696","HK0000306685.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655862873","title":"Shanghai Henlius Doses First Patient in Phase 1 Trial of Prostate Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2655862873","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655862873?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:24","pubTimestamp":1785407079,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech  said it has dosed the first patient in a Phase 1 clinical trial of HLX3902, its internally developed trispecific antibody, for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors in mainland China.The company also plans to begin the corresponding Phase 1 study in Australia once the required conditions are met, according to a Hong Kong bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000165453.HKD","HK0000306701.USD","02696","HK0000306685.HKD","BK1161","HK0000320264.USD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156171231","title":"First Patient Dosed in Phase 1 Trial of Henlius' HLX3902 for Metastatic Castration-Resistant Prostate Cancer and Other Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1156171231","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156171231?lang=en_us&edition=fundamental","pubTime":"2026-07-30 17:30","pubTimestamp":1785403830,"startTime":"0","endTime":"0","summary":"Henlius (02696) has announced that the first patient has been dosed in a Phase 1 clinical study evaluating its self-developed HLX3902 injection, a STEAP1xCD3xCD28 trispecific antibody, for the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000165453.HKD","BK1161","HK0000320264.USD","02696","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653078918","title":"Shanghai Henlius Biotech (SEHK:2696) Advances Pipeline As Fair Value Questions Grow","url":"https://stock-news.laohu8.com/highlight/detail?id=2653078918","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653078918?lang=en_us&edition=fundamental","pubTime":"2026-07-22 02:33","pubTimestamp":1784658838,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (SEHK:2696) has moved into focus after dosing the first patient in an international multicenter phase 1 trial of its nivolumab biosimilar HLX18 for multiple resected solid tumors.\nSee our latest analysis for Shanghai Henlius Biotech.\nDespite the clinical progress, Shanghai Henlius Biotech’s share price has been under pressure in recent months, with a 30 day share price return of down 5.79% and a 90 day share price return of down 28.49%. The 3 year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-advances-pipeline-as-fair","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/shanghai-henlius-biotech-sehk2696-advances-pipeline-as-fair","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","FEBU","XBI","HK0000306701.USD","DCF","BK4585","RGLO","HK0000320223.HKD","HK0000320264.USD","02696","BK4588","BK4581","GXDW","HK0000306685.HKD","JOYT","HK0000165453.HKD","DECU","PMDE","VOTE","VGFPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652289657","title":"Shanghai Henlius Biotech Grants 4.13 Million Share Options at HK$ 62.28 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2652289657","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652289657?lang=en_us&edition=fundamental","pubTime":"2026-07-17 22:27","pubTimestamp":1784298439,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech grants 4.13 million share options at HK$ 62.28 eachShanghai Henlius Biotech set new equity awards, granting 4,130,000 H-share options to 27 participants, grant date July 17, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL5D1CfG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","HK0000320223.HKD","HK0000165453.HKD","BK1161","HK0000320264.USD","HK0000306701.USD","BK1230","02696","00656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651434364","title":"Henlius Biotech Doses First Patient in Tumor Drug Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2651434364","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651434364?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:17","pubTimestamp":1784197023,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical study of HLX18, according to a Thursday Hong Kong bourse filing.The drug is being tested in patients with multiple resected solid tumors in Mainland China.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000306701.USD","BK4581","BK4588","HK0000165453.HKD","BK1161","HK0000320264.USD","BK4585","HK0000306685.HKD","HK0000320223.HKD","02696","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172209298","title":"Henlius doses first patient in global Phase 1 trial of nivolumab biosimilar HLX18 for multiple solid tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=1172209298","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172209298?lang=en_us&edition=fundamental","pubTime":"2026-07-16 16:44","pubTimestamp":1784191463,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (Henlius, 02696) has initiated patient dosing in an international, multicentre Phase 1 clinical study evaluating its independently developed nivolumab biosimilar HLX18...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651430491","title":"Chinese Drugmakers with Big Ambitions Struggle to Recruit Staff for Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2651430491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651430491?lang=en_us&edition=fundamental","pubTime":"2026-07-16 07:00","pubTimestamp":1784156400,"startTime":"0","endTime":"0","summary":"ANALYSIS-Chinese drugmakers with big ambitions struggle to recruit staff for global expansionDrug development from Chinese companies has grown significantly over the past two decadesEfforts to expand ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nL6N42V0LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","LU1580142542.USD","LU1969619763.USD","LU1255011170.USD","00656","HK0000320223.HKD","LU2488822045.USD","HK0000165453.HKD","LU1997244956.HKD","LU2097828557.USD","LU2097828631.EUR","LU1064131003.USD","BK0028","BK0196","LU0405327494.USD","HK0000320264.USD","LU1997245177.USD","LU1781817850.SGD","BK1230","LU2148510915.USD","BK1161","BK0188","LU1146622755.USD","BK0060","LU2097828805.USD","LU2580892862.HKD","LU2495084118.USD","LU1064130708.USD","LU0405327148.USD","688185","LU2328871848.SGD","LU2097828714.EUR","LU2097828474.EUR","LU1997245094.SGD","LU1655091616.SGD","02696","LU2580892789.USD","BK0239","LU1820825898.SGD","600276","BK0183","HK0000306685.HKD","HK0000306701.USD","LU2289578879.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184389225","title":"Hong Kong Market Analysis: Longxun's IPO Valuation Sets Benchmark, Stirring Tech Sector; \"Lab Monkey\" Prices Drive CXO Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1184389225","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184389225?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:43","pubTimestamp":1784119436,"startTime":"0","endTime":"0","summary":"The Hong Kong market has recently shown signs of moving independently, with its current trend aligning well with its internal structure. While the A-share market declined, Hong Kong stocks have...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0300738514.USD","HK0000500386.USD","LU0359202008.SGD","LU1969619763.USD","LU0390135688.USD","HK0000306685.HKD","LU0359201612.USD","BK4585","02343","LU0390135332.USD","BK1564","06127","VXUS","HK0000306701.USD","01801","BK1589","LU2242644610.SGD","BK1103","LU2488822045.USD","SG9999001093.SGD","LU0049112450.USD","02696","BK1501","LU1023057109.AUD","LU1235295612.USD","SG9999003461.SGD","03908","BK1583","LU0300738605.USD","SG9999011746.SGD","LU2097828805.USD","BK1147","LU0455707207.USD","KCAI","SG9999002828.SGD","HK0000165453.HKD","BK1576","BK1141","HK0000252152.HKD","CXO","06066","LU2097828631.EUR","HK0000252160.HKD","LU0502904849.HKD","LU0390135506.SGD","HK0000320223.HKD","LU2328871848.SGD","SG9999002950.SGD","BK1516","BK1535","LU0359201885.HKD","LU2097828474.EUR","BK4588","HK0000320264.USD","LU2097828557.USD","LU1046422090.SGD","IPOS","KURE","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188098063","title":"HENLIUS's Global Drug H Gains Momentum, Accelerating Commercial Value Realization","url":"https://stock-news.laohu8.com/highlight/detail?id=1188098063","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188098063?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:10","pubTimestamp":1783930252,"startTime":"0","endTime":"0","summary":"The global commercial strategy for HENLIUS's key oncology drug is progressing rapidly, with its value increasingly recognized in international markets.At the recent \"First Gastric Cancer...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","02696","HK0000320223.HKD","BK1161","HK0000320264.USD","HK0000306685.HKD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650518161","title":"Shanghai Henlius Biotech's Cancer Drug Combination Trial Gets IND Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2650518161","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650518161?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:12","pubTimestamp":1783678326,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (HKG:2696) said its investigational new drug application for a Phase I clinical trial of HLX37 in combination with chemotherapy or HLX43 has been approved by China's National ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000320223.HKD","HK0000320264.USD","HK0000306701.USD","IND","XBI","BK1161","HK0000165453.HKD","HK0000306685.HKD","BK4581","02696","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126218869","title":"HENLIUS secures NMPA green light for Phase 1 study of bispecific antibody HLX37 with chemotherapy or ADC HLX43 in advanced solid tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=1126218869","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126218869?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:45","pubTimestamp":1783673101,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech, Inc. (HENLIUS, 02696.HK) disclosed that China’s National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application to initiate a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0598},{"period":"3month","weight":-0.003},{"period":"6month","weight":-0.0434},{"period":"1year","weight":-0.1513},{"period":"ytd","weight":0.1797}],"compareEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0326},{"period":"6month","weight":-0.0546},{"period":"1year","weight":-0.0158},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.033714},{"month":6,"riseRate":0.571429,"avgChangeRate":0.085211},{"month":7,"riseRate":0.428571,"avgChangeRate":0.040127},{"month":8,"riseRate":0.571429,"avgChangeRate":0.009153},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"HENLIUS","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HENLIUS,02696,HENLIUS股票,HENLIUS股票老虎,HENLIUS股票老虎国际,HENLIUS行情,HENLIUS股票行情,HENLIUS股价,HENLIUS股市,HENLIUS股票价格,HENLIUS股票交易,HENLIUS股票购买,HENLIUS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HENLIUS(02696),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HENLIUS(02696) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}